Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.36 |
| ▸ | HTR2C | P28335 | 6/20 | 0.36 |
| ▸ | HTR2B | P41595 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.33 |
| ▸ | PNMT | P11086 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5317749 | 0.85 | TP53 (0.38) | HTR2ATP53MEN1KMT2ACLCN2 | |
| SCHEMBL4812657 | 0.83 | HTR2A (0.39) | HTR2AHTR2CHTR2BRAPGEF4LMNA | |
| SCHEMBL29449511 | 0.81 | ALDH1A1 (0.37) | RAPGEF4ADRA2ATP53MEN1NPC1 | |
| SCHEMBL15497514 | 0.81 | ALDH1A1 (0.37) | RAPGEF4ADRA2ATP53MEN1NPC1 | |
| SCHEMBL13755137 | 0.79 | ALDH1A1 (0.36) | RAPGEF4ADRA2ATP53MEN1NPC1 | |
| SCHEMBL12225802 | 0.79 | RAPGEF4 (0.33) | HTR2AHTR2CHTR2BRAPGEF4ADRA2A | |
| SCHEMBL29620412 | 0.79 | ALDH1A1 (0.36) | HTR2AHTR2CHTR2BRAPGEF4ADRA2A | |
| SCHEMBL7550352 | 0.79 | ALDH1A1 (0.36) | HTR2AHTR2CHTR2BRAPGEF4ADRA2A | |
| SCHEMBL8249627 | 0.79 | ACHE (0.36) | HTR2AHTR2CHTR2BCYP3A4RAPGEF4 | |
| SCHEMBL900037 | 0.77 | ALDH1A1 (0.42) | HTR2AHTR2CHTR2BCYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4273147-A1 | SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-11-08 | — | — | EP | disclosed |
| CN-110937994-B | Method for synthesizing 2, 4-dichloro-6-fluorobenzoyl chloride by two-step chlorination process | 浙江大洋生物科技集团股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| WO-2021043322-A1 | AZEPINO PYRIMIDINE DERIVATIVES AND MEDICAL USE THEREOF | 正大天晴药业集团南京顺欣制药有限公司 | 2021-03-11 | — | — | WO | disclosed |
| CN-110937994-A | Method for synthesizing 2, 4-dichloro-6-fluorobenzoyl chloride by two-step chlorination process | 浙江大洋生物科技集团股份有限公司 | 2020-03-31 | — | — | CN | disclosed |
| US-9914712-B2 | Antibacterial thiazolecarboxylic acids | ANTABIO SAS (FR) | 2018-03-13 | — | — | US | disclosed |
| CN-103044181-A | Method for preparing octene-1 by ethylene tetramerization reaction | PETROCHINA CO LTD | 2013-04-17 | — | — | CN | disclosed |
| US-20130023562-A1 | NOVEL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-01-24 | — | — | US | disclosed |
| US-8314127-B2 | Piperidine derivatives | ASTRAZENECA AB (SE) | 2012-11-20 | — | — | US | disclosed |
| EP-1912941-B1 | PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-11-14 | — | — | EP | disclosed |
| EP-2402316-A1 | Piperidine derivatives | AstraZeneca AB (Publ) (SE) | 2012-01-04 | — | — | EP | disclosed |
| US-20090253929-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| US-20080207688-A1 | Novel Piperidine Derivatives | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| EP-1912941-A1 | NOVEL PIPERIDINE DERIVATIVES | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1824806-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2007-08-29 | — | — | EP | disclosed |
| WO-2007011293-A1 | NOVEL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006062477-A1 | CHEMICAL PROCESS | ASTRAZENECA AB (SE) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006062476-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-06-15 | — | — | WO | disclosed |
| CN-1651142-A | Catalyst component used for ethylene oligomerization, preparing process and application thereof | DAQING PETROCHEMICAL BRANCH CO (CN) | 2005-08-10 | — | — | CN | disclosed |
| CN-1108193-C | Novel catalyst for ethylene trimerization, its preparation process and application | RES INST BEIJING YANSHAN PETRO (CN) | 2003-05-14 | — | — | CN | disclosed |
| CN-1256968-A | Novel catalyst for ethylene trimerization, its preparation process and application | RES INST BEIJING YANSHAN PETRO (CN) | 2000-06-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207688-A1 | Novel Piperidine Derivatives | CCR3, CCR1, CCR4 | HTR2A 3423/4885HTR2C 2235/4885HTR2B 2351/4885 |
| US-20130023562-A1 | NOVEL PIPERIDINE DERIVATIVES | CCR3, CCR1, CCR4 | HTR2A 3423/4885HTR2C 2235/4885HTR2B 2351/4885 |
| US-20090253929-A1 | Chemical Compounds | CYP4B1, CYP3A4, CYP1A1 | HTR2A 3541/4885HTR2C 1953/4885HTR2B 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.